 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Arrowhead Offers Timeline for HBV Candidate, Plans Two Phase I Trials
February 14, 2013
Arrowhead Offers Timeline for HBV Candidate, Plans Two Phase I Trials
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Arrowhead Presents Preclinical Data on HBV Candidate, Subcutaneous Delivery Tech
November 8, 2012 / Gene Silencing News - Arrowhead Names HBV as Next RNAi Program While It Consolidates Operations
February 16, 2012 / Gene Silencing News - Arrowhead Publishes Rodent, Primate Data on Preclinical Hepatitis B Therapy
February 28, 2013 / Gene Silencing News - Arrowhead Publishes Primate Data on Co-Delivery Approach for Cholesterol-Conjugated siRNAs
November 29, 2012 / Gene Silencing News - Arrowhead Takes Last Steps toward Moving HBV Drug into Human Testing
June 7, 2012 / Gene Silencing News